Zacks.com on MSN6h
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
MeiraGTx Holdings: Promising Growth Potential with Strategic Manufacturing and Positive Clinical Results
Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Meiragtx Holdings (MGTX – Research Report). The ...
FierceBiotech1d
MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial
MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ...
MeiraGTx gains as gene therapy shows promise in Parkinson’s
MeiraGTx Holdings (NASDAQ:MGTX) added ~14% in the premarket on Tuesday after the New York-based biotech announced promising ...
pharmaphorum13h
MeiraGTx plans to take Parkinson's gene therapy into phase 3
According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local production of GABA, a neurotransmitter that can help restore more normal ...
bovnews11h
MeiraGTx Holdings PLC (MGTX) Stock: Greater Than Its Current Valuation?
On Tuesday, MeiraGTx Holdings PLC (MGTX) stock saw a modest uptick, ending the day at $5.33 which represents a slight increase of $0.69 or 14.87% from the prior close of $4.64. The stock opened at $5.
precisionmedicineonline6h
MeiraGTx to Discuss Parkinson's Gene Therapy Data With Regulators, Planning Phase III Trial
The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints
MeiraGTx's clinical study of AAV-GAD for Parkinson's disease showed significant improvements in motor function and quality of ...
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH ...
MeiraGTx帕金森氏症基因疗法试验结果积极
伦敦和纽约 - 临床阶段基因医学公司MeiraGTx Holdings plc (NASDAQ:MGTX)宣布其最新临床试验MGT-GAD-025取得令人鼓舞的结果。该试验旨在治疗帕金森氏症,达到了主要的安全性和耐受性目标,同时在特发性帕金森氏症患者的关键疗效终点上也显示出显著改善。